Fluvoxamine Shows Promise in Reducing Long COVID Fatigue

For millions of people living with long COVID, fatigue isn’t just feeling tired—it’s a debilitating exhaustion that can make working or caring for a family nearly impossible. As the most common symptom of the condition, finding an effective treatment has been a priority for researchers. A recent study published in the Annals of Internal Medicine suggests that a widely available antidepressant, fluvoxamine, may offer significant relief.

The Study: Testing Fluvoxamine Against Fatigue

Researchers conducted a randomized clinical trial involving 399 participants, all of whom suffered from significant fatigue. To ensure a standardized baseline, researchers used the Fatigue Severity Scale, a validated seven-point measure where participants rate their level of exhaustion. Every person in the trial started with a score of at least four points. a score of seven represents the worst possible fatigue.

The trial compared the effects of fluvoxamine—a low-cost and accessible antidepressant—against a placebo to determine if the drug could meaningfully lower these fatigue ratings.

Key Findings and Results

The results indicated that fluvoxamine provided a noticeable improvement in fatigue levels, particularly in the short term:

• 30-Day Mark: Participants taking fluvoxamine were nearly 50% more likely than the placebo group to see their fatigue rating drop to a three or less.
• 60-Day Mark: The medication lowered self-reported fatigue ratings by nearly half a point.
• Overall Well-being: Beyond just fatigue, those taking fluvoxamine reported a better overall quality of life and experienced fewer adverse events than those in the placebo group.

Fluvoxamine vs. Metformin

The study didn’t just look at antidepressants; it also tested metformin, a diabetes medication known to aid prevent long COVID. Yet, when it came to treating existing fatigue, metformin didn’t perform any better than the placebo. This suggests that while some drugs may prevent the onset of long COVID, others, like fluvoxamine, are better suited for managing specific symptoms after they’ve developed.

“I think fluvoxamine’s done great,” said study co-author Jamie Forrest, PhD, MPH, scientific director of the University of British Columbia’s Health Equity & Resilience Observatory. Forrest noted that the ultimate goal is to help patients acquire back to feeling normal.

Understanding the Complexity of Long COVID

While these results are encouraging, medical experts emphasize that long COVID is a complex condition. It involves multiple biological pathways and a wide variety of symptoms that may not all respond to the same treatment. Researchers highlight that while fluvoxamine is a promising option for managing fatigue, it is one piece of a larger puzzle in treating the syndrome.

Key Takeaways

• Effective Relief: Fluvoxamine significantly reduces fatigue in long COVID patients within two to three months.
• Improved Quality of Life: Patients reported feeling better overall and experienced fewer side effects than those on a placebo.
• Accessibility: Fluvoxamine is a low-cost, widely available medication.
• Specific Action: Unlike metformin, which did not alleviate fatigue in this trial, fluvoxamine showed clear efficacy for this specific symptom.

Frequently Asked Questions

What is the Fatigue Severity Scale?

It is a validated seven-point scale used by clinicians to measure the level of tiredness or exhaustion a person feels. A higher score indicates more severe fatigue.

Is fluvoxamine a standard treatment for long COVID?

While this randomized clinical trial provides strong evidence that it can reduce fatigue and improve quality of life, long COVID remains a complex condition. Patients should consult their healthcare provider to see if this medication is appropriate for their specific symptoms.

How does fluvoxamine compare to metformin for fatigue?

In this specific trial, fluvoxamine was effective in reducing fatigue, whereas metformin did not provide more relief than a placebo.

Looking Ahead

The discovery that a low-cost, existing medication can alleviate the most common symptom of long COVID is a significant step forward. As researchers continue to map the biological pathways of the condition, the focus remains on developing targeted therapies that can return patients to their normal daily activities and improve their long-term quality of life.